Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
105.8 USD | -0.13% | -1.61% | -3.88% |
04-29 | Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee | MT |
04-26 | Dexcom's profit beats estimates on strong glucose monitor demand | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.88% | 184B | |
-1.09% | 107B | |
-3.47% | 69.44B | |
+3.30% | 50.37B | |
+8.55% | 44.82B | |
+3.40% | 41.53B | |
+2.77% | 26.84B | |
+3.97% | 26.73B | |
+15.23% | 25.71B | |
-0.99% | 24.34B |
- Stock Market
- Equities
- ABT Stock
- News Abbott Laboratories
- Morgan Stanley Adjusts Abbott Laboratories' Price Target to $117 from $126, Keeps Overweight Rating